🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06766773
Active, not recruiting Not applicable

Composite Warming Strategy Reduces Intraoperative Hypothermia in Open Hepatectomy for Liver Cancer

NCT06766773 · tracked via the Priya Life Science China tracker
Sponsor
The First People's Hospital of Neijiang
Phase
Not applicable
Started
2020-01-01
Last updated
2025-01-10

Condition(s) studied

HCC

Investigational drug(s) / intervention(s)

Compound heating strategyperioperative mandatory warming measures

Compound heating strategy: After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.

perioperative mandatory warming measures: perioperative mandatory warming measures

Study summary

The composite warming strategy has a certain effect on preventing hypothermia during cancer liver resection surgery. This study aims to explore the application of compound warming strategy in perioperative nursing of cancer liver resection.

This study will compare two groups: the control group using perioperative forced warming measures, and the experimental group using a composite warming strategy.

Main objective: Intraoperative temperature changes Secondary objective: incidence of complications The investigators' investigated the practicality and effectiveness of a combined warming strategy in open liver resection surgery. In addition, the investigators also conducted a quantitative correlation study on the incidence of hypothermia during the surgical process. This provides evidence-based guidance for the prevention of hypothermia during surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 75 years. * Scheduled for elective open hepatectomy to treat hepatocellular carcinoma, confirmed by preoperative biopsy or imaging. * Adequate liver function (Child-Pugh score A or B). * American Society of Anesthesiologists (ASA) physical status classification of I, II, or well-controlled III. * Informed consent provided for participation. Exclusion Criteria: * Aged under 18 or over 75 years. * Metastatic liver disease or emergency liver surgery required. * Chronic analgesic use that could interfere with pain assessment. * Participation in another clinical trial within the past 30 days. * Contraindications to warming devices (e.g., certain skin conditions or advanced peripheral vascular disease). * Pregnant or lactating. * Presence of an implantable device (e.g., pacemakers or defibrillators) that could be affected by warming strategies. * Cognitive impairment or psychiatric disorders affecting study understanding or informed consent. * Use of medications/substances impacting thermoregulation (e.g., illicit drugs, alcohol abuse, antipyretics). * History of malignancies other than liver cancer affecting survival or perioperative risk. * Recent history (within six months) of myocardial infarction or cerebrovascular accident. * Uncontrolled diabetes mellitus or other significant endocrine disorders. * Severe anemia (hemoglobin below a predetermined threshold).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First People's Hospital of Neijiang Neijiang Sichuan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06766773 on ClinicalTrials.gov ↗ ← All trials in China